Versican Plus DHPPi

RSS

canine distemper, canine adenovirus, canine parvovirosis and canine parainfluenza virus vaccine (live attenuated)

Authorised
This medicine is authorised for use in the European Union.

Overview

This is a summary of the European Public Assessment Report. Its purpose is to explain how the assessment done by the Committee for Medicinal Products for Veterinary Use (CVMP) on the basis of the documentation provided, led to the recommendations on the conditions of use.

This summary cannot replace a face-to-face discussion with your veterinarian. If you need more information about your animal’s medical condition or treatment, contact your veterinarian. If you want more information on the basis of the CVMP recommendations, read the scientific discussion (also part of the EPAR).

This EPAR was last updated on 16/05/2019

Authorisation details

Product details
Name
Versican Plus DHPPi
Agency product number
EMEA/V/C/003679
Active substance
canine distemper virus, strain CDV Bio 11/A, canine adenovirus type 2, strain CAV-2 Bio 13, canine parvovirus type 2b, strain CPV-2b Bio 12/B and canine parainfluenza type 2 virus, strain CPiV-2 Bio 15 (all live attenuated)
International non-proprietary name (INN) or common name
canine distemper, canine adenovirus, canine parvovirosis and canine parainfluenza virus vaccine (live attenuated)
Species
Dogs
Anatomical therapeutic chemical veterinary (ATCvet) codes
QI07AD04
Publication details
Marketing-authorisation holder
Zoetis Belgium SA
Revision
7
Date of issue of marketing authorisation valid throughout the European Union
03/07/2014
Contact address
Rue Laid Burnait, 1
1348 Louvain-la-Neuve
Belgium

Product information

17/04/2019 Versican Plus DHPPi - EMEA/V/C/003679 - IB/0014

Contents

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

  • IMMUNOLOGICALS FOR CANIDAE
  • Live viral vaccines

Therapeutic indication

Active immunisation of dogs from six weeks of age.

  • to prevent mortality and clinical signs caused by canine distemper virus,
  • to prevent mortality and clinical signs caused by canine adenovirus type 1,
  • to prevent clinical signs and reduce viral excretion caused by canine adenovirus type 2,
  • to prevent clinical signs, leukopenia and viral excretion caused by canine parvovirus,

to prevent clinical signs and reduce viral excretion caused by canine parainfluenza virus.

Assessment history

How useful was this page?

Add your rating